Cittadine Andrew 4

What Happened
Andrew Cittadine, Chief Operating Officer of Monopar Therapeutics (MNPR), had restricted stock units (RSUs) vest and convert into 3,514 shares of common stock on March 31, 2026. The company withheld 1,571 of those shares to satisfy tax withholding obligations at $54.79/share (total withheld value $86,075), leaving a net of 1,943 shares added to his beneficial ownership. This was an RSU settlement (compensation), not an open‑market purchase.

Key Details

• Transaction date: March 31, 2026; Form 4 filed April 2, 2026 (timely filing).
• Lines reported:
  • Code M (conversion of derivative): 3,514 shares acquired (RSU settlement) — no cash price.
  • Code F (payment of tax liability): 1,571 shares withheld/disposed at $54.79 each = $86,075.
  • Code M (disposition of derivative): 3,514 RSUs surrendered/converted (reported at $0.00).
• Net shares added to beneficial ownership from this event: 1,943 shares (3,514 acquired − 1,571 withheld).
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Relevant footnotes: RSU grants described (Feb 1, 2023 and Mar 4, 2025 grants with multi‑year vesting schedules); withheld shares used to pay applicable withholding taxes.
• No indication of a 10b5‑1 plan; this was routine compensation vesting rather than a market purchase or sale.

Context
This was a routine vesting/settlement of RSUs (a derivative converting into common stock). The shares withheld to cover taxes are a standard cashless/withholding settlement and do not by themselves indicate a buy or sell sentiment. The filing appears timely (filed within the required two business days).